XML 39 R19.htm IDEA: XBRL DOCUMENT
v3.22.2.2

JOINT VENTURES AND ASSOCIATES | 12 Months Ended
--- | ---
Jun. 30, 2022
JOINT VENTURES AND ASSOCIATES |
JOINT VENTURES AND ASSOCIATES | 13. JOINT VENTURES AND ASSOCIATES ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 06/30/2022 |  | 06/30/2021 |  | 06/30/2020
Assets | ​ | ​ | ​ | ​ | ​ | ​
Synertech Industrias S.A. |  | 35,646,740 |  | 27,572,597 |  | 24,619,773
Indrasa Biotecnología S.A. |  | 70,466 |  | 54,957 |  | 33,019
Alfalfa Technologies S.R.L. |  | 74,827 |  | 97,920 |  | —
Moolec Science Limited | ​ | 2,759,059 | ​ | 2,931,699 | ​ | —
Moolec Science S.A. | ​ | 3,000 | ​ | — | ​ | —
​ |  | 38,554,092 |  | 30,657,173 |  | 24,652,792
​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 06/30/2022 |  | 06/30/2021 |  | 06/30/2020
Liabilities |  |  |  |  |  |
Trigall Genetics S.A. |  | 717,948 |  | 1,278,250 |  | 1,548,829
​ |  | 717,948 |  | 1,278,250 |  | 1,548,829
​ Changes in joint ventures investments and affiliates: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 06/30/2022 |  | 06/30/2021 |  | 06/30/2020
As of the beginning of the year |  | 29,378,923 |  | 23,103,963 | ​ | 23,350,125
Monetary contributions |  | — |  | 101,883 | ​ | —
Non-monetary contributions (Note 12) |  | 3,000 |  | 2,931,699 | ​ | 250,000
Revaluation of property, plant and equipment |  | (586,268) |  | (413,618) | ​ | 521,406
Share-based incentives | ​ | 50,315 | ​ | — | ​ | —
Foreign currency translation |  | 7,845,756 | ​ | 2,657,567 | ​ | (3,494,761)
Share of profit or loss |  | 1,144,418 | ​ | 997,429 | ​ | 2,477,193
As of the end of the year |  | 37,836,144 | ​ | 29,378,923 | ​ | 23,103,963
​ Share of profit or loss of joint ventures and affiliates: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 06/30/2022 |  | 06/30/2021 |  | 06/30/2020
Trigall Genetics S.A. |  | 670,065 | ​ | 270,579 | ​ | 171,502
Synertech Industrias S.A. |  | 856,006 | ​ | 708,550 | ​ | 2,294,332
Moolec Science Limited |  | (383,447) | ​ | — | ​ | —
Indrasa Biotecnología S.A. |  | 1,794 | ​ | 18,300 | ​ | 11,359
​ |  | 1,144,418 | ​ | 997,429 | ​ | 2,477,193
​ There are no significant restrictions on the ability of the joint ventures and affiliates to transfer funds to the Group for cash dividends, or to repay loans or advances made by the Group, except for the Argentinian legal obligation to establish a legal reserve for 5% of the profit for the year until reaching 20% of the capital for Argentinian entities. Summarized financial information prepared in accordance with International Financial Reporting Standards (“IFRS”) in relation to the joint ventures is presented below: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Trigall Genetics
Summarized balance sheet |  | 06/30/2022 |  | 06/30/2021 |  | 06/30/2020
Current assets | ​ | ​ | ​ | ​ | ​ | ​
Cash and cash equivalents |  | 36,479 |  | 13,798 |  | 1,331
Other current assets |  | 3,787,140 |  | 1,949,590 |  | 1,024,793
Total current assets |  | 3,823,619 |  | 1,963,388 |  | 1,026,124
Non-current assets |  | ​ |  | ​ |  | ​
Intangible assets |  | 14,485,757 |  | 13,335,653 |  | 11,776,705
Total non-current assets |  | 14,485,757 |  | 13,335,653 |  | 11,776,705
Current liabilities |  | ​ |  | ​ |  | ​
Other current liabilities |  | 1,638,939 |  | 1,257,070 |  | 869,700
Total current liabilities |  | 1,638,939 |  | 1,257,070 |  | 869,700
Non-current liabilities |  | ​ |  | ​ |  | ​
Financial liabilities | ​ | 13,947,658 | ​ | 12,184,030 | ​ | 10,831,048
Other non- current liabilities |  | 745,008 |  | 1,000,774 |  | 831,685
Total non-current liabilities |  | 14,692,666 |  | 13,184,804 |  | 11,662,733
Net assets |  | 1,977,771 |  | 857,167 |  | 270,396
​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Trigall Genetics
Summarized statements of comprehensive income |  | 06/30/2022 |  | 06/30/2021 |  | 06/30/2020
Revenue |  | 2,205,849 |  | 1,110,303 |  | 799,625
Finance income |  | — |  | 22,470 |  | 79,442
Finance expense |  | (97,419) |  | (3,586) |  | (1,863)
Depreciation and amortization | ​ | (234,190) | ​ | — | ​ | —
Profit of the year |  | 1,340,129 |  | 586,773 |  | 172,670
Total comprehensive income |  | 1,340,129 |  | 586,773 |  | 172,670
​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Synertech
Summarized balance sheet |  | 06/30/2022 |  | 06/30/2021 |  | 06/30/2020
Current assets |  | ​ |  |  |  |
Cash and cash equivalents |  | 202,078 |  | 540,149 |  | 18,251
Other current assets |  | 39,346,866 |  | 17,274,878 |  | 17,983,868
Total current assets |  | 39,548,944 |  | 17,815,027 |  | 18,002,119
Non-current assets |  | ​ |  | ​ |  | ​
Property, plan and equipment |  | 13,846,826 |  | 13,422,832 |  | 14,168,459
Other non- current assets |  | — |  | 39,171 |  | —
Total non-current assets |  | 13,846,826 |  | 13,462,003 |  | 14,168,459
Current liabilities |  | ​ |  | ​ |  | ​
Financial liabilities |  | 6,995,247 |  | 1,346,327 |  | 5,484,866
Other current liabilities |  | 17,684,155 |  | 6,807,330 |  | 4,719,276
Total current liabilities |  | 24,679,402 |  | 8,153,657 |  | 10,204,142
Non-current liabilities |  | ​ |  | ​ |  | ​
Financial liabilities |  | 84,391 |  | 331,306 |  | 2,783,951
Other non- current liabilities |  | 3,257,934 |  | 4,119,471 |  | 2,554,905
Total non-current liabilities |  | 3,342,325 |  | 4,450,777 |  | 5,338,856
Net assets |  | 25,374,043 |  | 18,672,596 |  | 16,627,580
​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Synertech
Summarized statements of comprehensive income |  | 06/30/2022 |  | 06/30/2021 |  | 06/30/2020
Revenue |  | 61,117,486 |  | 23,759,744 |  | 21,501,725
Finance income |  | 7,019,720 |  | 5,584,007 |  | 3,805,655
Finance expense |  | (8,644,475) |  | (6,283,955) |  | (6,666,508)
Depreciation and amortization |  | (1,339,357) |  | (39,171) |  | (1,076,699)
(Loss)/Profit of the year |  | (2,429,401) |  | 1,776,244 |  | 5,099,582
Other comprehensive (loss)/income |  | (1,172,537) |  | (827,236) |  | 1,042,811
Total comprehensive (loss)/income |  | (3,601,938) |  | 949,008 |  | 6,142,393
​

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfJointVenturesAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of joint ventures. [Refer: Joint ventures [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2022-03-24 -Paragraph 17 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard -URIDate 2022-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2022-03-24 -Paragraph 16 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard -URIDate 2022-03-24 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2022-03-24 -Paragraph B4 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_b&doctype=Appendix&subtype=B -URIDate 2022-03-24 + Details
Name: | ifrs-full_DisclosureOfJointVenturesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration